Is CD39 finally ready for a breakout moment in lung cancer? Innate Pharma tests the thesis
Innate Pharma’s IPH5201 posted encouraging Phase 2 lung cancer data at AACR 2026. Read what it could change for perioperative NSCLC treatment.
Agenus AACR 2026 data show immune reprogramming signal in PD-1 refractory gastroesophageal cancer
Read how Agenus’ AACR 2026 data could reshape treatment sequencing in refractory gastroesophageal cancer and what risks still matter.
Could Ampligen become a late-stage pancreatic cancer breakthrough after AIM ImmunoTech’s latest clinical push?
Can Ampligen’s Phase 3 push reshape pancreatic cancer treatment? Read how AIM ImmunoTech’s latest clinical progress could change the oncology outlook.
Can TAE Life Sciences turn BNCT into a credible radio-immunotherapy platform for hard-to-treat cancers?
TAE Life Sciences’ BNCT study showed stronger boron delivery and immune effects in preclinical models. Read what this could change for oncology.
Can IASO Bio and Instituto Butantan make CAR-T therapy affordable for Brazil’s public health system?
IASO Bio and Instituto Butantan are betting on local CAR-T development in Brazil. Find out what this could change for access, cost, and cancer care.
Why ABION’s ABN202 may be aiming beyond TROP2 antibody-drug conjugate resistance
ABION’s ABN202 showed preclinical promise against TROP2 ADC resistance at AACR 2026. Read what this could mean for solid tumor oncology.
What Innate Pharma’s Kempen conference participation reveals about its 2026 biotech strategy
Innate Pharma heads to Kempen as investors assess its oncology pipeline, partnering outlook, and next catalysts. Read the full analysis.
What the Agenus-MiNK Therapeutics combination reveals about the next phase of GI cancer immunotherapy
Agenus brings botensilimab, balstilimab, and agenT-797 to AACR 2026. Read why this refractory GEC update matters and what risks remain.
How Incyte’s retifanlimab approval could reshape first-line therapy for advanced anal cancer in Europe
European regulators approve retifanlimab for advanced anal cancer. Discover what this means for immunotherapy treatment strategies in rare oncology today.
Merck’s KEYTRUDA plus WELIREG cuts recurrence risk in Phase 3 LITESPARK-022 trial for adjuvant clear cell renal cell carcinoma
KEYTRUDA plus belzutifan cuts recurrence risk in adjuvant RCC. Explore what LITESPARK-022 changes for kidney cancer treatment.